The press release you shared only announces when Y‑mAbs Therapeutics will report its second‑quarter 2025 results (before the market opens on Friday, August 8, 2025). It does not contain any forward‑looking financial guidance—i.e., it does not provide projected revenue, net profit (or loss), earnings per share, or any other monetary figures for Q2 2025.
What this means for your question
- Projected revenue for Q2 2025: Not disclosed in the announcement.
- Projected net profit (or loss) for Q2 2025: Not disclosed in the announcement.
Next steps if you need the figures
- Monitor the upcoming earnings release – The actual numbers will be published on or shortly after August 8, 2025, either via a detailed earnings press release, an SEC Form 8‑K, or an earnings call transcript.
- Check Y‑mAbs’ investor‑relations website – Companies typically post the earnings release, presentation slides, and a webcast replay there.
- Look for analyst coverage – Some brokerage firms may publish pre‑earnings estimates that could give you a sense of market expectations, though those are not official company guidance.
- Set up alerts – Services like Bloomberg, FactSet, or even Google Finance can notify you when the Q2 2025 results become public.
Until the company’s official results are released, we simply do not have the projected revenue or net‑profit figures. If you obtain a later release or a reliable analyst forecast, feel free to share it and I can help interpret the numbers.
Other Questions About This News
What are the margins and cost trends reported for the quarter?
Will the earnings release include any updates on FDA filings or regulatory milestones?
Will there be any announcements of new partnerships, licensing deals, or collaborations?
How will Y-mAbs' Q2 2025 earnings compare to consensus analyst estimates?
Will the company provide updated guidance for FY 2025 and FY 2026?
How might the earnings outcome affect short‑term trading strategies (e.g., options, volatility trades)?
How have recent clinical trial results or pipeline updates affected expectations?
How does the recent performance compare to peer biopharma companies in the antibody oncology space?
Are there any notable changes in cash burn or cash runway that could affect liquidity?
What is the expected impact on YMAB's share price volatility around the earnings release?